VPA is a drug with pleiotropic effects and our in-depth analysis suggests VPA has many targets and may ultimately work through multiple mechanisms to inhibit the growth of IDH1 MT gliomas but that at least some of the mechanistic effect is mediated by FASN as summarized in Fig. 8F. The gene discussed is FASN; the disease is central nervous system cancer.